Evidence map›Paper›PMID 32579593›Full record

ArticlePLoS pathogens2020

Rapid in vitro generation of bona fide exhausted CD8+ T cells is accompanied by Tcf7 promotor methylation.

Manzhi Zhao, Caoimhe H Kiernan, Christopher J Stairiker, Jennifer L Hope, Leticia G Leon, Marjan van Meurs, Inge Brouwers-Haspels, Ruben Boers, Joachim Boers, Joost Gribnau and 6 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. DUSP4 promotes anti-tumor CD8Nature communications · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Reversing T cell dysfunction in a novelFrontiers in immunology · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Manzhi ZhaoDepartment of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Caoimhe H KiernanDepartment of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-4113-3160
Christopher J StairikerDepartment of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Jennifer L HopeCancer Immunology and Tumor Microenvironment Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States of America.ORCID 0000-0002-2363-5442
Leticia G LeonDepartment of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0001-8781-7424
Marjan van MeursDepartment of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Inge Brouwers-HaspelsDepartment of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Ruben BoersDepartment of Developmental Biology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-3377-2897
Joachim BoersDepartment of Developmental Biology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Joost GribnauDepartment of Developmental Biology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Wilfred F J van IJckenCenter for Biomics, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-0421-8301
Eric M BindelsDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Remco M HoogenboezemDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Stefan J ErkelandDepartment of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-1019-7957
Yvonne M MuellerDepartment of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-4654-7509
Peter D KatsikisDepartment of Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0001-7690-5218
Erasmus MC · NLSanford Burnham Prebys Medical Discovery Institute · US

Funding

Worldwide Cancer Research 16-1153
6 · The paper itself

Abstract

Exhaustion is a dysfunctional state of cytotoxic CD8+ T cells (CTL) observed in chronic infection and cancer. Current in vivo models of CTL exhaustion using chronic viral infections or cancer yield very few exhausted CTL, limiting the analysis that can be done on these cells. Establishing an in vitro system that rapidly induces CTL exhaustion would therefore greatly facilitate the study of this phenotype, identify the truly exhaustion-associated changes and allow the testing of novel approaches to reverse or prevent exhaustion. Here we show that repeat stimulation of purified TCR transgenic OT-I CTL with their specific peptide induces all the functional (reduced cytokine production and polyfunctionality, decreased in vivo expansion capacity) and phenotypic (increased inhibitory receptors expression and transcription factor changes) characteristics of exhaustion. Importantly, in vitro exhausted cells shared the transcriptomic characteristics of the gold standard of exhaustion, CTL from LCMV cl13 infections. Gene expression of both in vitro and in vivo exhausted CTL was distinct from T cell anergy. Using this system, we show that Tcf7 promoter DNA methylation contributes to TCF1 downregulation in exhausted CTL. Thus this novel in vitro system can be used to identify genes and signaling pathways involved in exhaustion and will facilitate the screening of reagents that prevent/reverse CTL exhaustion.

Indexed as

AnimalsCD8-Positive T-LymphocytesDNA MethylationHepatocyte Nuclear Factor 1-alphaLymphocytic ChoriomeningitisLymphocytic choriomeningitis virusMiceMice, TransgenicPromoter Regions, GeneticSignal TransductionHepatocyte Nuclear Factor 1-alphaHnf1a protein, mouse

Identifiers

PMID32579593
PMCPMC7340326
OpenAlexW3037786483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.